Human T lymphotropic virus type II infection and humoral responses to pneumococcal polysaccharide and tetanus toxoid vaccines.
Infection with human T lymphotropic virus type II (HTLV-II) has been linked to an increased incidence of bacterial pneumonia. To determine whether HTLV-II infection is associated with impaired humoral immune responses, we immunized a cohort of HTLV-II-infected subjects and matched uninfected control subjects with 23-valent pneumococcal polysaccharide and tetanus toxoid vaccines. The pneumococcal polysaccharide vaccine elicited comparable and significant increases in concentrations of IgG against all 5 serotypes tested at 1 and 6 months after immunization in both groups. The avidity and opsonophagocytic functions of the anticapsular IgG were similar. The concentrations of tetanus toxoid-specific IgG also increased comparably and significantly over time in both groups. Thus, HTLV-II-infected persons develop robust humoral responses to potentially protective polysaccharide and protein vaccines.
Jarvis
Gary A
GA
Department of Laboratory Medicine, University of California at San Francisco, San Francisco, California 94121, USA. jarvis@itsa.ucsf.edu
Janoff
Edward N
EN
Cheng
Hui
H
Devita
Deborah
D
Fasching
Claudine
C
McCulloch
Charles E
CE
Murphy
Edward L
EL
D000328:Adult; D000368:Aged; D000915:Antibody Affinity; D015331:Cohort Studies; D005260:Female; D015491:HTLV-II Infections / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007074:Immunoglobulin G / Q000276:immunology; D016018:Least-Squares Analysis; D008297:Male; D008875:Middle Aged; D010587:Phagocytosis; D022242:Pneumococcal Vaccines / Q000276:immunology*; D013296:Streptococcus pneumoniae / Q000145:classification / Q000276:immunology; D013745:Tetanus Toxoid / Q000276:immunology*; D013997:Time Factors
D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines; D013745:Tetanus Toxoid